PubMed Health⌕ Search

Biomedical subjects

G S Patton

Publications and source records attributed to G S Patton.

10 recordsLinked to original sources
PubMed1977

Pancreatic immunoreactive somatostatin release.

The location of the somatostatin-containing D-cells of the pancreatic islets between the A- and B-cells suggests that their function might be to inhibit insulin and/or glucagon secretion by these neighboring cells. To determine if insulin and/or glucagon, in concentrations that might be present in the extracellular space surrounding the D-cells, stimulate immunoreactive somatostatin (IRS) release, we perfused 10 microng of glucagon or 10 milliunits of insulin per ml in 11 isolated dog pancreases, for 40 min in seven experiments and for 100 min in four experiments. In eight of the nine experiments in which glucagon was perfused, a prompt and significant rise in mean IRS release, ranging from 71 to 128% above the control level, was observed. In the eight experiments in which insulin was perfused. IRS did not increase during the first 40 min; in the two 100-min insulin experiments, it did rise during the final 50 min, however. To determine the effect of an A- and B-cell secretogogue on IRS release, we perfused 20 mM arginine for 60 min in six experiments. In all, IRS rose within 3 min and reached a level 71-465% above the control, remaining significantly elevated throughout the perfusion, while glucagon and insulin rose to peak levels at 2 min and then declined somewhat despite continuing arginine perfusion. The results indicate that perfusion of the normal dog pancreas with high doses of glucagon or arginine is accompanied by a prompt increase in IRS release and are compatible with a local feedback circuit involving A- and D-cells. Insulin appears not to augment IRS release, at least not promptly, but IRS stimulated by local endogenous glucagon could inhibit the B-cell response to locally secreted glucagon and thereby influence the composition of the insulin/glucagon secretion mixture.

Animals↗
PubMed1977

Demonstration of gastric glucagon hypersecretion in insulin-deprived alloxan-diabetic dogs.

The contribution of the gastric fundus to the hyperglucagonemia of poorly controlled diabetes was studied in insulin-deprived alloxan-diabetic dogs by simultaneously measuring plasma glucagon in the venous effluents of the fundus and the pancreas, and the inferior vena cavae plasma. In the basal state, mean glucagon averaged 411 +/- 45 pg./ml. in the gastric vein and 941 +/-161 in the pancreaticoduodenal vein; both values were significantly above the vana caval level of 281 +/-35 (p less than 0.01). Intravenous arginine infusion to 1,180 +/- 432 after 1.5 minutes; this was significantly above the mean vena caval glucagon concentration which reached a peak of only 352 +/- 74 (p less than 0.01 to 0.05). Intragastric instillation of arginine was followed by a doubling of gastric vein glucagon within 10 minutes, and the increases in the gastric vein were significantly greater than in the peripheral plasms at several points. The infusion of insulin at a rate of 0.0015 u./kg./min. rapidly lowered glucagon in the gastric and pancreaticoduodenal veins, abolishing the gradient across the stomach and reducing the transpancreatic gradient. The studies raise the possibility that extrapancreatic glucagon may contribute to the hyperglucagonemia of insulin deficiency.

Animals↗
PubMed1976

Gastric A-cell function in normal dogs.

Glucagon release from the gastric fundus and pancreas were compared in normal dogs by measuring glucagon in plasma from a major gastroepiploic vein, the superior pancreaticoduodenal vein, and the inferior vena cava. In 32 dogs in the basal state, gastric vein glucagon averaged 97 +/- 40 pg/ml, not significantly different from the 93 +/- 41 pg/ml level in the vena cava. Pancreaticoduodenal vein glucagon averaged 250 +/- 32 pg/ml (P less than 0.001). Intravenous arginine infused in four dogs caused a rise in mean gastric vein glucagon to 210 +/- 33 pg/ml within 3 min, and glucagon remained between 53 and 98 pg/ml above the vena caval level thereafter. In the gastric vein, the rise in glucagon was significantly greater than in the vena cava at 3, 5, and 10 min (P less than 0.05), but was far less than in the pancreaticoduodenal vein where glucagon rose to 1,295 +/- 379 pg/ml at 1.5 min. Evidence of modest gastric glucagon release was observed after the intragastric instillation of arginine, but not during insulin or phloridzin-induced hypoglycemia. It was concluded that in normal dogs under the circumstances studied, the gastric fundus is not a major source of circulating glucagon.

Animals↗
PubMed1976

Gastric A-cell function in insulin-deprived depancreatized dogs.

To determine if gastric A-cells are a major source of the glucagonemia of insulin-deprived depancreatized dogs and to examine their secretory behavior, immunoreactive glucagon (IRG) was measured simultaneously in plasma from the inferior vena cava (VC) and from a gastric vein (GV) draining the fundus. Basal GV IRG averaged 205 +/- 35 pg/ml, significantly above the VC level of 71 +/- 30 (P less than 0.001) and rose to 1417 +/- 498 1.5 minutes after the start of an arginine infusion, exceeding VC IRG at all points (P less than 0.01). Measurement of IRG in gastric, jejunal, and ileal veins and vena cava revealed an IRG gradient only across the stomach. Measurement of glucagon-like immunoreactivity (GLI) revealed no gradient across the stomach, jejunum, or ileum, thus excluding cross-reaction with GLI as the cause of the GV hyperglucagonemia. Intragastric arginine elicited a near doubling of GV IRG within 1.5 minutes and this persisted for at least 120 minutes, ranging from 142 to 623 pg/ml above the VC level. Infusion of insulin at a physiologic rate lowered GV IRG from 665 +/- 66 to 151 +/- 49 pg/ml in 20 minutes and abolished the GV-VC gradient within 60 minutes, whereas intravenous and intragastric glucose administration without insulin did not alter GV IRG. It is concluded that: 1) in the insulin-deprived depancreatized dog, the stomach is a major source of IRG; 2) gastric IRG secretion is somehow stimulated by intravenous and intragastric arginine administration; 3) it is not influenced by intravenous or intragastric glucose administration; and 4) its release is suppressed by physiologic levels of insulin.

Animals↗